Download the Agenda


Resource Centre

Featured Download

PDFPDF

  • Improving Clinical Outcomes For Faster ApprovalsImproving Clinical Outcomes For Faster Approvals
    A firm’s awareness on how to counter discovery challenges and improve clinical outcomes is vital to them being able to beat others to market with their immune checkpoint modulation offering.

    With this in mind, Pharma IQ dissects these challenges and identifies the latest developments and tactics in regards to improving clinical outcomes for faster approvals with immune checkpoint inhibitors.
  • Interactive Immune Checkpoint Modulator Venture MapInteractive Immune Checkpoint Modulator Venture Map
    This buzz of attention has propelled the R&D race in the immune checkpoint modulator arena, which boasts an optimistic pipeline of therapies with all eyes set on obtaining blockbuster status.
    Pharma IQ presents this immune checkpoint modulator venture map, providing an overview of various companies developing products in
    the space and the cancers of focus.
  • Combination Therapies with Immune Checkpoint InhibitorsCombination Therapies with Immune Checkpoint Inhibitors
    Pharma IQ shares this case study from AgonOx, a biotechnology company focused on cancer immunotherapy, focusing on the value of partnerships, challenges faced in successfully developing ICI's and adapting to the future trends in this market. 

ArticlesArticles

  • Pipeline Immunotherapies Show Promise for Non-small Cell Lung Cancer Market
    Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three late-stage candidates leading the way, according to independent analyst firm Datamonitor Healthcare. Drugs including nivolumab (Bristol-Myers Squibb), pembrolizumab (Merck & Co) and MPDL3280A (Roche) – which all target the PD-1 signaling pathway – are expected to become the first treatments of this modality, with nivolumab set to hit the market first in 2015. 
  • Roche and Merck Collaborate to Develop Diagnostic Tests for Merck's Investigational Cancer Therapies
    WHITEHOUSE STATION, N.J. and PLEASANTON, Calif., June 7, 2011 - Merck (NYSE:MRK), known outside the United States and Canada as MSD, and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that they have entered into a collaboration focused on the application and development of diagnostic assays for use with Merck's investigational cancer therapy portfolio. Financial details were not disclosed. "We are very pleased to showcase our leadership position in personalized healthcare by entering into this agreement with Merck. Roche hopes that, through our joint efforts, we will be able to provide companion diagnostic tests which lead to better solutions for patients worldwide." said Paul Brown, Head of Roche Molecular Diagnostics. The collaboration will apply various technologies such as array and immunohistochemical (IHC/ISH) technologies. Roche Diagnostics will provide validated, standardized assays for use in clinical oncology programs being conducted by Merck. Merck will
  • Predictive Biomarkers Provide Momentum to Cancer Treatments
    Advancements continue to be made in the use of biomarkers to predict the growth of cancerous cells. Argonaute proteins were recently reported to be over-expressed in colon cancer relative to adjacent non-cancer tissue. Journal BMC Cancer revealed new research that the expression of EIF2C2-4 and PIWIL4 appears increased in advanced tumors with distant metastasis, indicating that it could possibly promote tumor development. In addition, EIF2C1 and PIWIL2 may also represent novel colon cancer markers with early diagnostic significance. Meanwhile, the Jonsson Comprehensive Cancer Center at UCLA has found that histone modifications can be used to predict prognosis and response to pancreatic cancer treatments in subsets of patients. Researchers, who had previously shown that low cellular levels of particular histones could determine which prostate cancer patients were more likely to suffer a recurrence and which patients with lung and kidney cancers would experience poorer survival

PDFPDF

  • The R&D Race behind Immune Checkpoint ModulatorsThe R&D Race behind Immune Checkpoint Modulators
    The cancer immunotherapy market is primed for growth, with Immune Checkpoint Inhibitors, otherwise known as Immune Checkpoint Modulators, representing one of the area’s newest and most promising treatments. While also incorporating the focus on cancer vaccines and adoptive T-cell therapies, the global cancer immunotherapy market is expected to climb to $9 billion by 2022 according to a statement within the Cancer Immunotherapy Market.

Sponsorship Opportunities

Resource Center

Visit the Resource Center for complimentary industry related content!

IDGA

Become a Pharma IQ Member and receive our weekly newsletter!